Latest Articles & Resources FEATURED Aldevron and IDT Manufacture First Personalised CRISPR Therapy for Infant with UCD Read More » Aldevron and IDT Manufacture First Personalised CRISPR Therapy for Infant with UCD Read More » LATEST NEWS + INTERVIEWS Cybin Engages Thermo Fisher for Phase 3 and Commercial Manufacturing of CYB003 SK pharmteco Expands Stability Storage Capacity by 40% at California CDMO Site Kincell Bio Secures $22M to Expand Cell Therapy CDMO Capabilities AGC Biologics Partners with Quell Therapeutics to Advance Treg Cell Therapy Programs Skyepharma Advances Oncology Contract Manufacturing with French Facility Launch TriLink BioTechnologies and IVI Partner to Advance mRNA Vaccine Development 3PBIOVIAN Launches AAVion Platform to Streamline Gene Therapy Manufacturing Terumo to Acquire WuXi Biologics’ German Plant for €150M Forge Biologics Partners with Fractyl Health on AAV Manufacturing for Metabolic Gene Therapy FAMAR Expands CDMO Network with Sterile Manufacturing Site in Germany Accelerating Drug Development Through Drug Substance and Drug Product Integration CellFE and Made Scientific Partner on Pilot for Non-Viral T Cell Engineering Benuvia Operations Signs Multi-Year Dronabinol API Supply Agreement Recipharm Forms Strategic CDMO Alliance with ProductLife Group “Nobody Knows Anything”: Gil Roth on Policy Volatility Under Trump Administration eXmoor Pharma Partners with KU Leuven to Advance AAV Gene Therapy Hub Novopor Acquires Pressure Chemical to Expand Specialty Chemistry CDMO Platform Piramal Pharma to Invest $90M to Expand US Manufacturing Facilities Building Resilience in Life Sciences: Preventing Burnout in High-Stakes Drug Development CDMO Live Report 2025 [DOWNLOAD] BioWell Assumes Operations of Texas BioTechnology’s 13,000L CDMO Facility PODCAST INTERVIEWS “Nobody Knows Anything”: Gil Roth on Policy Volatility Under Trump Administration Building Resilience in Life Sciences: Preventing Burnout in High-Stakes Drug Development Beyond Auditing: How Qualifyze Proactively Manages Risk in Uncertain Times